Suraksha Diagnostic Limited share price
Suraksha Diagnostic Limited provides pathological and radiological services through diagnostic centers in India. It offers home collection services; pathology services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, haematology, clinical biochemistry and immunology, immunohistochemistry, fluorescence in-situ hybridization, cytogenetics, flow cytometry, newborn screening, and NGS. The company also provides microarray, QF-PCR, FISH, karyotyping, and NIPT services; X-Ray, MRI scan, CT scan, USG, DEXA scan, Mammography, OPG radiology services; ECG, echocardiogram, stress test and treadmill test, wireless holter monitoring, and PFT cardiolog…Read more
- Market Cap₹ 1,597 Cr.
- Current Price₹ 306.70
- High / Low₹ 360 / 224
- Stock P/E44.6
- Book Value₹ 47
- Dividend Yield0.16 %
- ROCE14.7 %
- ROE14.10 %
- Face Value₹ 2.0
More figures (10)
- EPS (TTM)₹ 6.88
- Price / Book6.50
- OPM17.9 %
- Debt / Equity0.53
- Sales growth (4Y)17.7 %
- Profit growth (4Y)70.3 %
- Promoter holding62.0 %
- EV / EBITDA15.8
- Beta—
- All-time high₹ 449
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| SURAKSHA | -6.15% | +18.01% | +8.80% | +13.74% | +2.18% | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Suraksha Diagnostic Limited is in the Diagnostics & Research industry (Healthcare), with a market value of ₹1,597 crore.
- It trades at 44.6 times its last 12 months' earnings and 6.5 times book value.
- Revenue grew 17.7% a year over the last 4 years, profit 70.3% a year.
- Return on equity was 14.1% and return on capital employed 14.7% in the latest year.
- Debt was 0.53 times shareholders' equity.
- The share price is 14.8% below its 52-week high and up 2.2% over one year.
- Promoters and insiders hold about 62.0%; institutions about 21.5%.
Pros
AI- Latest quarter (Jun 2026): sales up 21% and profit up 40% from a year ago.
- Healthy return on equity of 14.8% on average over the last 3 years.
Cons
AINo standout weaknesses in the reported figures.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Suraksha Diagnostic Limited
Suraksha Diagnostic Limited provides pathological and radiological services through diagnostic centers in India. It offers home collection services; pathology services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, haematology, clinical biochemistry and immunology, immunohistochemistry, fluorescence in-situ hybridization, cytogenetics, flow cytometry, newborn screening, and NGS. The company also provides microarray, QF-PCR, FISH, karyotyping, and NIPT services; X-Ray, MRI scan, CT scan, USG, DEXA scan, Mammography, OPG radiology services; ECG, echocardiogram, stress test and treadmill test, wireless holter monitoring, and PFT cardiology services; EEG, EMG, and NCV neurology services; and upper GI and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy gastroenterology services. In addition, it offer…
- Employees
- 1,600
- Head office
- Kolkata
Peer comparison
HealthcareDiagnostics & Research
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Suraksha Diagnostic | 306.70 | 44.6 | 1,597 | 0.16 | 13 | 40.00 | 88 | 20.75 | 14.7 | 14.1 | 6.50 | 17.9 | 0.53 | 61.97 | 310 | 17.7 |
| 2. | Dr. Lal PathLabs | 1,859.90 | 57.4 | 31,100 | 1.06 | 171 | 27.24 | 798 | 19.10 | 25.7 | 21.6 | 12.38 | 37.1 | 0.08 | 54.70 | 2,763 | 11.1 |
| 3. | Sai Life Sciences | 1,389.40 | 82.1 | 29,521 | 0.00 | 73 | -16.98 | 554 | -4.35 | 18.1 | 15.1 | 11.83 | 21.9 | 0.12 | 36.28 | 2,137 | 21.3 |
| 4. | Syngene International | 386.10 | 70.3 | 15,518 | 0.33 | -9 | -104.91 | 736 | -27.70 | 8.3 | 6.6 | 3.21 | 15.4 | 0.09 | 52.82 | 3,611 | 5.4 |
| 5. | Vijaya Diagnostic Centre | 1,381.70 | 76.0 | 14,231 | 0.14 | 53 | 37.61 | 231 | 22.83 | 19.1 | 19.7 | 14.85 | 30.1 | 0.44 | 53.48 | 814 | 21.0 |
| 6. | Metropolis Healthcare | 530.35 | 54.6 | 11,002 | 0.38 | 57 | 25.76 | 450 | 16.62 | 15.7 | 13.4 | 7.27 | 18.1 | 0.15 | 47.82 | 1,646 | 12.8 |
| 7. | Thyrocare Technologies | 485.25 | 44.0 | 7,723 | 1.91 | 51 | 34.06 | 240 | 24.34 | 33.8 | 28.8 | 13.19 | 24.9 | 0.09 | 51.18 | 829 | 16.7 |
| Median: 7 Co. | 530.35 | 57.4 | 14,231 | 0.33 | 53 | 27.24 | 450 | 19.10 | 18.1 | 15.1 | 11.83 | 21.9 | 0.12 | 52.82 | 1,646 | 16.7 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own past sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
No separate related-party filing among the recent announcements of the company.
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| 252 | 310 | 323 | |
| YOY Sales Growth % | 23.14% | ||
| 171 | 215 | 221 | |
| Material Cost % | 12% | 12% | 12% |
| Employee Cost % | 17% | 17% | 17% |
| Other Expenses % | 39% | 40% | 40% |
| Operating Profit | 81 | 95 | 102 |
| OPM % | 32% | 31% | 32% |
| Other Income | 4 | 3 | 4 |
| Interest | 8 | 13 | 14 |
| Depreciation | 35 | 41 | 43 |
| Profit before tax | 41 | 45 | 50 |
| 25% | 30% | 27% | |
| Current tax | 10 | 11 | |
| Deferred tax | 0 | 2 | |
| 31 | 31 | 36 | |
| Minority share | -1 | -1 | -0 |
| Profit to shareholders | 32 | 32 | 28 |
| YOY Profit Growth % | 1.37% | ||
| EPS in Rs | 5.97 | 6.18 | 7.00 |
Compounded Sales Growth
- TTM:
- 23%
Compounded Profit Growth
- TTM:
- 11%
Stock Price CAGR
- 1 Year:
- 2%
Return on Equity
- 4 Years:
- 12%
- Last Year:
- 14%
| ₹ Cr | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| 249 | 301 | 314 | |
| YOY Sales Growth % | 20.71% | ||
| 167 | 206 | 215 | |
| Material Cost % | 12% | 12% | 12% |
| Employee Cost % | 17% | 17% | 17% |
| Other Expenses % | 38% | 39% | 40% |
| Operating Profit | 83 | 95 | 100 |
| OPM % | 33% | 32% | 32% |
| Other Income | 4 | 4 | 5 |
| Interest | 8 | 12 | 13 |
| Depreciation | 35 | 40 | 41 |
| Profit before tax | 44 | 47 | 50 |
| 24% | 28% | 27% | |
| Current tax | 10 | 11 | |
| Deferred tax | 0 | 2 | |
| 33 | 34 | 37 | |
| YOY Profit Growth % | 1.86% | ||
| EPS in Rs | 6.42 | 6.54 | 7.07 |
Compounded Sales Growth
- TTM:
- 21%
Compounded Profit Growth
- TTM:
- 5%
Stock Price CAGR
- 1 Year:
- 2%
Return on Equity
- 4 Years:
- 12%
- Last Year:
- 14%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 7 | 7 | 10 | 10 |
| Reserves | 149 | 173 | 201 | 234 |
| 97 | 90 | 89 | 130 | |
| Long term borrowings | 8 | 5 | 3 | 0 |
| Short term borrowings | 6 | 3 | 3 | 2 |
| 28 | 30 | 33 | 73 | |
| Trade payables | 14 | 14 | 14 | 21 |
| Minority interest | -0 | -0 | -1 | -1 |
| Current liabilities | 38 | 39 | 43 | 60 |
| Total Liabilities | 281 | 300 | 334 | 448 |
| 196 | 216 | 239 | 353 | |
| Gross block | 227 | 278 | 334 | 489 |
| Accumulated depreciation | 31 | 62 | 95 | 136 |
| Goodwill & intangibles | 1 | 1 | 2 | 7 |
| CWIP | 3 | 6 | 18 | 43 |
| 82 | 78 | 77 | 53 | |
| Inventories | 6 | 7 | 8 | 8 |
| Trade receivables | 5 | 9 | 14 | 23 |
| Cash & equivalents | 2 | 3 | 2 | 3 |
| Current assets | 68 | 72 | 47 | 63 |
| Total Assets | 281 | 300 | 334 | 448 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 44 | 60 | 63 | 82 | |
| Profit for the year | 7 | 24 | 32 | 32 |
| Working capital changes | 5 | -4 | -10 | -2 |
| Direct taxes paid | -7 | -9 | -11 | -13 |
| -21 | -35 | -40 | -52 | |
| Fixed assets purchased | -13 | -45 | -42 | -67 |
| Fixed assets sold | 1 | 3 | 0 | 0 |
| Investments purchased | -41 | -1 | ||
| Investments sold | 30 | 5 | ||
| -24 | -25 | -24 | -29 | |
| Proceeds from borrowings | 2 | 1 | 0 | |
| Repayment of borrowings | -7 | -6 | -3 | -4 |
| Interest paid | -1 | -1 | -1 | -0 |
| Net Cash Flow | -1 | 0 | -0 | 1 |
| Free Cash Flow | 31 | 15 | 21 | 14 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 4.2% | 14.1% | 16.3% | 14.1% |
| ROCE | — | 6.5% | 15.4% | 17.1% | 14.7% |
| Operating margin | — | 8.3% | 18.7% | 18.8% | 17.9% |
| Net margin | — | 3.4% | 10.8% | 12.6% | 10.4% |
| Debt / equity | — | 0.62 | 0.50 | 0.42 | 0.53 |
| Current ratio | — | 1.77 | 1.84 | 1.10 | 1.05 |
| Debtor days | — | 9 | 15 | 20 | 27 |
| Inventory days | — | 82 | 89 | 100 | 81 |
| Days payable | — | 187 | 193 | 169 | 209 |
| Cash conversion cycle | — | -96 | -89 | -49 | -101 |
| Working capital days | — | 57 | 55 | 6 | 3 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 49.10%
- FIIs 13.97%
- DIIs 21.56%
- Public 15.37%
| % | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 48.78% | 48.78% | 48.88% | 48.98% | 49.00% | 49.10% | 49.10% | 49.10% |
| 15.39% | 14.46% | 13.95% | 13.72% | 13.46% | 13.46% | 13.47% | 13.97% | |
| Foreign portfolio investors (Cat. I) | 2.51% | 1.58% | 1.06% | 0.85% | 0.58% | 0.58% | 0.59% | 0.75% |
| Foreign portfolio investors (Cat. II) | 0.01% | 0.35% | ||||||
| Foreign direct investment | 12.88% | 12.88% | 12.88% | 12.88% | 12.88% | 12.88% | 12.88% | 12.88% |
| 20.44% | 22.05% | 22.37% | 21.98% | 22.57% | 23.14% | 23.23% | 21.56% | |
| Mutual funds | 17.64% | 19.26% | 19.58% | 19.45% | 19.45% | 19.79% | 20.05% | 20.16% |
| Alternative investment funds | 2.48% | 2.79% | 2.79% | 2.53% | 3.12% | 3.35% | 3.17% | 1.40% |
| 15.39% | 14.70% | 14.80% | 15.31% | 14.98% | 14.31% | 14.21% | 15.37% | |
| Retail (up to ₹2 lakh) | 12.41% | 11.61% | 11.15% | 11.22% | 10.86% | 10.34% | 10.22% | 10.07% |
| HNIs (above ₹2 lakh) | 1.67% | 1.91% | 1.93% | 1.73% | 1.74% | 1.74% | 1.72% | 1.57% |
| NRIs | 0.10% | 0.08% | 0.10% | 0.18% | 0.23% | 0.21% | 0.20% | 0.24% |
| Bodies corporate | 0.66% | 0.64% | 1.17% | 1.68% | 1.68% | 1.56% | 1.58% | 3.01% |
| No. of Shareholders | 98,662 | 87,275 | 79,670 | 75,304 | 70,963 | 67,107 | 64,866 | 60,792 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Mutual funds & institutions holding Suraksha Diagnostic
| Holder (above 1%) | Stake |
|---|---|
| Nippon Life India Trustee Ltd-A/C Nippon India PhaMutual fund | 7.48% |
| Kotak Small Cap FundMutual fund | 6.99% |
| Aditya Birla Sun Life Trustee Private Limited A/CMutual fund | 3.79% |
| BANDHAN Balanced Advantage FundMutual fund | 1.09% |
As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 20.16% of the company. Shareholders below 1% are not named in the filing.
Documents
Announcements
- UpdatesSuraksha Diagnostic Limited has informed the Exchange regarding 'Board Comments on the Delay in Filing of the Shareholding Pattern with theNational Stock Exchange of India Limited…14-Oct-2026
- Change in Company Secretary/Compliance OfficerSuraksha Diagnostic Limited has informed the Exchange about Change in Company Secretary/Compliance Officer14-Oct-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Suraksha Diagnostic Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201805-Oct-2026
- Trading WindowSuraksha Diagnostic Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201528-Sep-2026
- Shareholders meetingVoting Results & Scrutinizer's Report for the 21st Annual General Meeting (AGM) ofthe Company held on 22nd September, 202624-Sep-2026
- Shareholders meetingRevised Proceedings of the 21st Annual General Meeting of the Company23-Sep-2026
- Shareholders meetingProceedings of 21st Annual General Meeting of the Company held on September 22, 2026.22-Sep-2026
- Copy of Newspaper PublicationSuraksha Diagnostic Limited has informed the Exchange about Copy of Newspaper Publication published today, i.e. on Monday, 31 August, 2026 with respect to the Notice of the 21st A…31-Aug-2026
- General UpdatesPursuant to Regulation 36(1)(b) of the SEBI Listing Regulations, a letter to those Members whose e-mail addresses are not registered with the Company/Registrar and Share Transfer …27-Aug-2026
- Shareholders meetingNotice of 21st Annual General Meeting to be held on September 22, 2026.27-Aug-2026
- Copy of Newspaper PublicationSuraksha Diagnostic Limited has informed the Exchange about Copy of Newspaper Publication25-Aug-2026
- Copy of Newspaper PublicationSuraksha Diagnostic Limited has informed the Exchange about Copy of Newspaper Publication25-Aug-2026
Annual reports
Credit ratings
Concalls & investor meets
- Analysts/Institutional Investor Meet/Con. Call UpdatesSuraksha Diagnostic Limited has informed the Exchange about Transcript17-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesSuraksha Diagnostic Limited has informed the Exchange about Transcript17-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesSuraksha Diagnostic Limited has informed the Exchange about Link of Recording13-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesSuraksha Diagnostic Limited has informed the Exchange about Link of Recording13-Aug-2026
- Investor PresentationSuraksha Diagnostic Limited has informed the Exchange about Investor Presentation12-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesSuraksha Diagnostic Limited has informed the Exchange about Schedule of meet06-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesSuraksha Diagnostic Limited has informed the Exchange about Transcript27-May-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesSuraksha Diagnostic Limited has informed the Exchange about Link of audio recording of the Earnings Call in relation to the audited (standalone and consolidated) financialresults …22-May-2026
- Investor PresentationSuraksha Diagnostic Limited has informed the Exchange about Investor Presentation21-May-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesSuraksha Diagnostic Limited has informed the Exchange about Schedule of meet15-May-2026
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 15 Sep 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
- UpdatesSuraksha Diagnostic Limited has informed the Exchange regarding 'Board Comments on the Delay in Filing of the Shareholding Pattern with theNational Stock Exchange of India Limited…NSE filing · 14-Oct-2026
- Change in Company Secretary/Compliance OfficerSuraksha Diagnostic Limited has informed the Exchange about Change in Company Secretary/Compliance OfficerNSE filing · 14-Oct-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Suraksha Diagnostic Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018NSE filing · 05-Oct-2026
- Trading WindowSuraksha Diagnostic Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 28-Sep-2026
- Shareholders meetingVoting Results & Scrutinizer's Report for the 21st Annual General Meeting (AGM) ofthe Company held on 22nd September, 2026NSE filing · 24-Sep-2026
- Shareholders meetingRevised Proceedings of the 21st Annual General Meeting of the CompanyNSE filing · 23-Sep-2026
- Shareholders meetingProceedings of 21st Annual General Meeting of the Company held on September 22, 2026.NSE filing · 22-Sep-2026
- Copy of Newspaper PublicationSuraksha Diagnostic Limited has informed the Exchange about Copy of Newspaper Publication published today, i.e. on Monday, 31 August, 2026 with respect to the Notice of the 21st A…NSE filing · 31-Aug-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Suraksha Diagnostic Limited
What is the share price of Suraksha Diagnostic Limited today?
What is the market cap of Suraksha Diagnostic Limited?
What is the P/E ratio of Suraksha Diagnostic Limited?
Is Suraksha Diagnostic Limited a good investment?
How can I buy Suraksha Diagnostic Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.